We are a clinical-stage, fully-integrated, pharmaceutical company committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our product pipeline consists of both small-molecule targeted therapies and large-molecule immunotherapies for the treatment of cancer and autoimmune diseases. We intend to build a diverse portfolio of innovative products through internal development, licensing, and strategic partnerships to increase our likelihood of success, diversify our longer-term revenue stream and deliver on our promise the bring innovative treatments to patients worldwide.